Showing 451-460 of 3014 results for "".
Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaTop Tips for Increasing Social Media Engagement
https://practicaldermatology.com/topics/practice-management/top-tips-for-increasing-social-media-engagement/23709/It takes time to grow your base, but if you know your audience and strategize, you can see gains.Rethink How You Market Your Practice During the Holidays
https://practicaldermatology.com/topics/practice-management/rethink-how-you-market-your-practice-during-the-holidays/23607/Winter can be the “gift that keeps on giving”—if you know how to leverage the season.Nailed It: Foods for Hair and Nails
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nailed-it-foods-for-hair-and-nails/19932/Zoe Draelos, MD is nuts about natural sources of nutrition and has some berry good news for those interested in alternative to supplements for the hair and nails. Hint: Not everyone needs supplements, she says.New SEO Trends Dermatologists Should Anticipate in 2021
https://practicaldermatology.com/topics/practice-management/new-seo-trends-dermatologists-should-anticipate-in-2021/19900/Dermatology online marketing will have a surge of possible business in 2021 as people start moving back to requesting and seeking medical care again, especially once COVID-19 vaccines become widespread. Getting ahead of the SEO search curve now will give your office the advantage before the demand mDermWireTV: Candela + Merz Aesthetics Partnership, COVID-19 Vaccines & Fillers, Almirall's Klisyri, MetSyn & PsO
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-candela-merz-aesthetics-partnership-covid-19-vaccines-and-fillers-almiralls-klisyri-metsyn-and-pso/19893/Klisyri® (tirbanibulin) ointment 1% from Almirall will be available for treatment of AKs by the end of this quarter; Ayman Grada, MD discusses. Are patients who have received dermal filler injections at risk for developing reactions to the COVID-19 vaccine? Joel L. Cohen, MD and Doris Day, MD weighDermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-zilxi-launch-eczema-awareness-uninsurance-rates/19863/For eczema awareness month, the National Eczema Association (NEA) is offering virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as new data fromScientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, ReCoding Challenges
https://practicaldermatology.com/topics/practice-management/coding-challenges/19741/Mark Kaufmann, MD discusses changing coding issues that will affect most dermatologists, including the need to get educated about new evaluation and management codes for 2021, modifier 25 issues, and global period codes being under pressure.Atopic Dermatitis: Rethinking the “Typical” Patient
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-rethinking-the-typical-patient/19666/It's possible to make generalities about the experience of atopic dermatitis, but it's increasingly clear that there is no "typical" patient. Zelma Chiesa Fuxench, MD discusses the latest findings on the signs and symptoms of AD and the populations affected.